Non-Small Cell Lung Cancer (NSCLC)

The European Commission approves the use of lorlatinib for the treatment of ALK-positive advanced non–small cell lung cancer.

The supplemental biologics license application for cemiplimab plus chemotherapy for patients with advanced non–small cell lung cancer was based on findings from the phase 3 EMPOWER-Lung 3 study and was accepted for review by the FDA.

Patients with stage IV non–small cell lung cancer treated with sugemalimab plus chemotherapy experienced a prolonged overall survival benefit compared with those who received placebo and chemotherapy.

The Japan Ministry of Health, Labour and Welfare granted approval to the KRAS inhibitor sotorasib for the treatment of adults with KRAS G12C–mutated non–small cell lung cancer.

Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.

Patients with stage IB to IIIA non–small cell lung cancer saw an improvement in disease-free survival when treated with pembrolizumab compared with the placebo regardless of PD-L1 expression.

Patients with locally advanced or metastatic EGFR exon 20–mutant non–small cell lung cancer may benefit from treatment with CLN-081, which was granted breakthrough therapy designation by the FDA.

Telisotuzumab vedotin’s breakthrough therapy designation for EGFR wild-type non–small cell lung cancer was supported by results from the phase 2 LUMINOSITY trial.

The combination of quaratusugene ozeplasmid immunogene therapy plus pembrolizumab was granted fast track designation by the US FDA for the treatment of patients with unresectable stage III or IV non–small cell lung cancer who previously progressed on pembrolizumab.

Patients with EGFR-mutated metastatic non–small cell lung cancer may achieve benefit from treatment with patritumab deruxtecan, which was granted breakthrough therapy designation by the FDA.

Zofia Piotrowska, MD, discusses potential therapies for patients with EGFR exon 20 insertion-positive non–small cell lung cancer.

The anti-TIGIT therapy tiragolumab administered in combination with atezolizumab showed clinically meaningful improvement at the 2.5-year follow-up vs atezolizumab alone for patients with PD-L1–positive metastatic non–small cell lung cancer.

Oncomine Dx Target Test has been approved by the FDA as a companion diagnostic to identify EGFR exon 20 insertion mutations in patients with non–small cell lung cancer who may undergo treatment with amivantamab.

The use of alectinib to treat ALK-positive non–small cell lung cancer resulted in better overall survival compared with ceritinib.

As the year 2021 comes to a close, CancerNetwork® reviews ongoing clinical research and upcoming innovations in the non–small cell lung cancer space.

Patients with EGFR-mutated non-squamous non–small cell lung cancer who progressed following EGFR-TKI therapy experienced a progression-free survival benefit following treatment with sintilimab plus a bevacizumab biosimilar injection and chemotherapy.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about the findings of the DESTINY-Lung01 study that were presented at 2021 ESMO.

The FDA granted Fast Track Designation to bemcentinib combined with a PD-L1 agent to treat patients with STK11 altered advanced/metastatic non–small cell lung cancer without actionable mutations.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about the rationale behind the TROPION-Lung04 trial using Dato-DXd plus durvalumab.

Findings from the CheckMate 816 trial indicated that the combination of nivolumab and chemotherapy as neoadjuvant therapy resulted in a significant event-free survival benefit for patients with resectable non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, and Federico Albrecht, MD, spoke about treating patients with EGFR-positive non–small cell lung cancer through randomized clinical trials and real-world studies.

Although canakinumab, an investigational interleukin-1β inhibitor, plus pembrolizumab did not meet the primary end points for locally advanced metastatic non–small cell lung cancer in the CANOPY-1 trial, it could have potential in certain patient subgroups.

A clinical pharmacy manager and a pharmacy resident detail the unique mechanism of action of tepotinib for metastatic non–small cell lung cancer with mutations in MET exon 14.

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

The VENTANA PD-L1 Assay, a companion diagnostic for atezolizumab in select patients with non–small cell lung cancer, was approved by the FDA based on the phase 3 Impower010 trial.

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to discuss differences in outcomes with immunotherapy agents in patients with wild-type and EGFR exon 20 insertion–positive non–small cell lung cancer.

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.